-
公开(公告)号:US20250009742A1
公开(公告)日:2025-01-09
申请号:US18699156
申请日:2022-10-12
Inventor: Nakcheol JEONG , Misun LEE , Heewoo SIM , Myungjin KIM , Jung-Hee KIM , Soo Bong HAN , Young Sik JUNG , Hye jin KIM , Chang Soo YUN , Heeyeong CHO , Mee Hyein KIM , Joo Youn LEE
IPC: A61K31/501 , A61K31/4155 , A61K31/4162 , A61K31/422 , A61K31/437 , A61K31/4439 , A61K31/506 , A61P31/20 , C07D231/12 , C07D231/16 , C07D231/56 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D471/04 , C07D491/052 , C07D491/056 , C07D495/04
Abstract: The present invention relates to a series of novel pyrazolylmethylurea derivatives, and the use thereof for the inhibition of capsid assembly and the prevention or treatment of viral diseases through the inhibition.
-
2.
公开(公告)号:US20230365582A1
公开(公告)日:2023-11-16
申请号:US18042352
申请日:2021-08-20
Inventor: Young Sook SHIN , Sang Kyun LIM , Yeri LEE , Donggeon KIM , Soo Bong HAN , Chang Soo YUN , Hyun Jin KIM , Joo Youn LEE , Hyuk LEE , Sikwang SEONG
IPC: C07D495/04 , C07D333/24 , C07D333/38 , C07D409/10 , C07D409/06
CPC classification number: C07D495/04 , C07D333/24 , C07D333/38 , C07D409/10 , C07D409/06
Abstract: The present application relates to a novel compound having inhibitory activity on prostaglandin E2 receptor and uses thereof, and provides a compound represented by formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a method of using the same.
-
公开(公告)号:US20250161271A1
公开(公告)日:2025-05-22
申请号:US18838591
申请日:2023-02-15
Inventor: Donggeon KIM , Yeri LEE , Sang Kyun LIM , Young Sook SHIN , Soo Bong HAN , Chang Soo YUN , Hyuk LEE , Hyun Jin KIM , Joo Youn LEE , Si Kwang SEONG , Taeyoung YOON , Youngrae LEE
IPC: A61K31/407 , A61K31/381 , A61K31/397 , A61K31/4155 , A61K31/4436 , A61K31/4535 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P35/00
Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising a novel compound that inhibits the activity of prostaglandin E2 receptor and an anticancer agent as active ingredients. The novel compound of the present invention inhibited the activity of prostaglandin E2 receptor and inhibited tumor growth in colorectal cancer and lung cancer tumor models. In addition, it was found that when administered in combination with other anticancer agents such as a chemotherapeutic agent and/or an immune checkpoint inhibitor, a synergistic effect was exhibited in anticancer activity. Therefore, a pharmaceutical composition for treating cancer, comprising the novel compound and an anticancer agent as active ingredients may be effectively used for the prevention and treatment of cancer.
-
公开(公告)号:US20210253544A1
公开(公告)日:2021-08-19
申请号:US17271354
申请日:2019-08-29
Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION , KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY , NATIONAL CANCER CENTER
Inventor: Bong-Jin LEE , Kyu-Yeon LEE , Sang Jae LEE , Dong-Gyun KIM , Joo Youn LEE , Kwan-Young JEONG , Heui Cherl YANG , Hyeon-Kyu LEE , Hyoun Sook KIM
IPC: C07D277/32 , A61P35/00 , A61P3/06
Abstract: A nicotinamide adenine dinucleotide phosphate-dependent steroid dehydrogenase-like (NSDHL) inhibitor provided according to an aspect of the present invention can be used not only as an anticancer agent capable of overcoming resistance to EGFR-targeting anticancer agents, but also advantageously in the treatment of hyperlipidemia.
-
公开(公告)号:US20200085803A1
公开(公告)日:2020-03-19
申请号:US16470014
申请日:2017-12-15
Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY , KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
Inventor: Sungchan CHO , Miri CHOI , Joo Youn LEE
IPC: A61K31/444 , A23L33/10
Abstract: The present invention relates to a pharmaceutical composition the prevention or treatment of DYRK-related diseases containing a pyridine-based compound as an active ingredient, a pyridine-based compound of the present invention which is used as an active ingredient of the pharmaceutical composition inhibits the activity of DYRK1A with very high efficacy and selectivity, thereby can be used effectively in the prevention or treatment of DYRK-related diseases, such as Down syndrome, degenerative brain diseases, cancer, and metabolic diseases.
-
公开(公告)号:US20200062730A1
公开(公告)日:2020-02-27
申请号:US16609805
申请日:2018-05-11
Inventor: Jong Yeon HWANG , Jae Du HA , Sung Yun CHO , Pil Ho KIM , Chang Soo YUN , Chi Hoon PARK , Chong Ock LEE , Sang Un CHOI , Joo Youn LEE , Sunjoo AHN
IPC: C07D401/04 , A61P35/00 , C07D401/14
Abstract: The present disclosure relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1 according to the present disclosure specifically binds with CRBN protein, and is involved in functions thereof. Therefore, the compound of the present disclosure can be favorably used in the prevention or treatment of leprosy, chronic graft versus host disease, an inflammatory disease, or cancer, which are caused by actions of CRBN protein.
-
-
-
-
-